Предикторы реперфузионного синдрома миокарда: современный взгляд на вопрос и актуальные проблемы. Часть 2: феномен невосстановленного коронарного кровотока, или феномен no-reflow (обзор литературы)

Несмотря на то, что феномен невосстановленного коронарного кровотока (no-reflow) давно известен, до сих пор нет однозначного мнения на счет предикторов, а соответственно, и групп риска его возникновения. Это препятствует прогнозированию дальнейшего течения заболевания и исследованию эффективности терапевтических и хирургических способов предотвращения последствий реперфузии у пациентов с инфарктом миокарда с подъемом сегмента ST, что, в свою очередь, ухудшает послеоперационный и отдаленный прогноз у данной группы больных. Для поиска исследований по этой проблеме мы использовали поисковые системы E-lilbrary, Google Scholar и Pubmed. В статье представлены данные исследований, освещающих предикторы феномена no-reflow, проведен их анализ. Также описаны сложности их выявления, поднята проблема диагностического подхода и формирования выборки для исследований. Дан обзор исследований, посвященных выявлению предикторов феномена no-reflow с помощью оптической когерентной томографии и внутрисосудистого ультразвукового исследования.

1. Kloner RA. Does reperfusion injury exist in humans // J. Am. Coll. Cardiol. 1993;(21):537–545. Doi: 10.1016/07351097(93)90700-b.

2. Durante A, Camici PG. Novel insights into an «old» phenomenon: the no reflow // Int. J. Cardiol. 2015;(187):273–280. Doi: 10.1016/j.ijcard.2015.03.359.

3. Schwartz BG, Kloner RA. Coronary no reflow // J. Mol. Cell Cardiol. 2012;52(4):873–882. Doi: 10.1016/j.yjmcc.2011.06.009.

4. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies // Eur. Heart J. 2001;(22):729–739. Doi: 10.1053/euhj.2000.2172.

5. Синдром реперфузии миокарда: патогенез, клиника, диагностика / Г. Г. Хубулава, А. Н. Шишкевич, С. С. Михайлов, Е. Ю. Бессонов // Вестн. Рос. Военно-мед. акад. – 2020. – Т. 1, № 69. – С. 196–200.

6. Фролов А. А., Починка И. Г., Шахов Б. Е. и др. Феномен коронарной микрососудистой обструкции (no-reflow) при проведении чрескожных коронарных вмешательств у пациентов с инфарктом миокарда // Патология кровообращения и кардиохирургия. – 2020. Т. 24, № 1. – С. 18–27.

7. Niccoli G, Cosentino N, Spaziani C. et al. No-reflow: incidence and detection in the cath-lab // Curr. Pharm. Des. 2013;(19):4564–4575. Doi: 10.2174/1381612811319250005.

8. Niccoli G, Scalone G, Lerman A. et al. Coronary microvascular obstruction in acute myocardial infarction // European Heart J. 2016;37(13):1024–1033. Doi: 10.1093/eurheartj/ehv484.

9. Morishima I, Sone T, Okumura K. et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction // J. Am. Coll. Cadiol. 2000;36(4):1202–1209. Doi: 10.1016/s0735-1097(00)00865-2.

10. Dong-bao L, Qi H, Zhi L. et al. Predictors and longterm prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction // Clin. Cardiol. 2010;33(12):7–12. Doi: 10.1002/clc.20634.

11. Mehta RH, Harjai KJ, Boura J. et al. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction // Am. J. Cardiol. 2003;92(12):1445–1447. Doi: 10.1016/j.amjcard.2003.08.056.

12. de Waha S, Patel MR, Granger CB. et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for STsegment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials // Eur. Heart J. 2017;38(47):3502–3510. Doi: 10.1093/eurheartj/ehx414.

13. Al Azzoni A, Lamelos P, Marsden T. Incidence and predictors of no reflow phenomenon: insights from the total trial // Journal of the American College of Cardiology. 2017;69(11):1179. Doi: 10.1016/s0735-1097(17)34568-0.

14. Cenko E, Ricci B, Kedev S. et al. The no-reflow phenomenon in the young and in the elderly // Int. J. of Cardiology. 2016;(222):1122–1128. Doi: 10.1016/j.ijcard.2016.07.209.

15. Lerman A, Holmes DR, Herrman J. et al. Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both // Eur. Heart J. 2007;28(7):788–797. Doi: 10.1093/eurheartj/ehl501.

16. Britten MB, Zeiher AM, Schächinger V. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron // Artery Dis. 2004;15(5):259–264. Doi: 10.1097/01.mca.0000134590.99841.81.

17. Nijveldt R, van der Vleuten PA, Hirsch A. et al. Early Electrocardiographic Findings and MR Imaging-Verified Microvascular Injury and Myocardial Infarct Size // JACC: Cardiovascular Imaging. 2009:2(10):1187–1194. Doi: 10.1016/j.jcmg.2009.06.008.

18. Niccoli G, Burzotta F, Galiuto L. et al. Myocardial noreflow in humans // J. Am. Coll. Cardiol. 2009;54(4):281–292. Doi: 10.1016/j.jacc.2009.03.054.

19. Sorajja P, Gersh BJ, Costantini C. et. al. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction // Eur. Heart J. 2005;26(7):667–674. Doi: 10.1093/eurheartj/ehi167.

20. Bolognese L, Carrabba N, Parodi G. et al. Impact of microvascular dysfunction on left ventricular remodeling and longterm clinical outcome after primary coronary angioplasty for acute myocardial infarction // Circulation. 2004;109(9):1121– 1126. Doi: 10.1161/01.cir.0000118496.44135.a7.

21. Wu KC, Zerhouni EA, Judd RM. et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction // Circulation. 1998;97(8):765–772. Doi: 10.1161/01.cir.97.8.765.

22. Fajar JK, Herianshyah T, Rohman MS. The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis // Indian Heart Journal. 2018;70(3):406–418. Doi: 10.1016/j.ihj.2018.01.032.

23. Kirma C, Izgi A, Dundar C. et al. Clinical and Procedural Predictors of No-Reflow Phenomenon After Primary Percutaneous Coronary Interventions // Circulation Journal. 2008;72(5):716–721. Doi: 10.1253/circj.72.716.

24. Sakai S, Mizuno K, Tomimura M. et al. Visualized plaque debris as a cause of distal embolization after percutaneous coronary intervention in patients with unstable angina // Catheter Cardiovasc. Interv. 2002;(55):113–117. Doi: 10.1002/ccd.10070.

25. den Heijer P, Foley DP, Escaned J. et al. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus // J. Am. Coll. Cardiol. 1994;24(3):649– 654. Doi: 10.1016/0735-1097(94)90010-8.

26. Soeda T, Higuma T, Abe N. et al. Morphological predictors for no reflow phenomenon after primary percutaneous coronary intervention in patients with STsegment elevation myocardial infarction caused by plaque rupture // Eur. Heart J. Cardiovasc. Imaging. 2017;18(1):103–110. Doi: 10.1093/ehjci/jev341.

27. Tanaka A, Kawarabayashi T, Nishibori Y. et al. No-Reflow Phenomenon and Lesion Morphology in Patients With Acute Myocardial Infarction // Circulation. 2002;105(18):2148– 2152. Doi: 10.1161/01.cir.0000015697.59592.07.

28. Iijima R, Shinji H, Ikeda N. et al. Comparison of coronary crterial finding by intravascular ultrasound in patients with «transient no-reflow» versus «reflow» during percutaneous coronary intervention in acute coronary syndrome // Am. J. Cardiol. 2006;97(1):29–33. Doi: 10.1016/j.amjcard.2005.07.104.

29. Endo M, Hibi K, Shimizu T. et al. Impact of ultrasound attenuation and plaque rupture as detected by intravascular ultrasound on the incidence of no-reflow phenomenon after percutaneous coronary intervention in st-segment elevation myocardial infarction // JACC Cardiovasc. Interv. 2010;3(5):540–549. Doi: 10.1016/j.jcin.2010.01.015.

30. Francischetti I, Moreno JB, Scholz M. et al. Leukocytes and the inflammatory response in ischemia-reperfusion injury // Rev. Bras. Cir. Cardiovasc. 2010;25(4):575–584. Doi: 10.1590/s0102-76382010000400023.

31. Akpek M, Kaya MG, Lam YY. et al. Relation of neutrophil/ lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with st-elevated myocardial infarction undergoing primary coronary intervention // Am. J. Cardiol. 2012;110(5):621–627. Doi: 10.1016/j.amjcard.2012.04.041.

32. Celik T, Kaya MG, Akpek M. et al. Predictive value of admission platelet volume indices for in-hospital major adverse cardiovascular events in acute st-segment elevation myocardial infarction // Angiology. 2013;66(2):155–162. Doi: 10.1177/0003319713513493.

33. Kurtul A, Acikgoz SK. Usefulness of mean platelet volume-to-lymphocyte ratio for predicting angiographic noreflow and short-term prognosis after primary percutaneous coronary intervention in patients with st-segment elevation myocardial infarction // Am. J. Cardiol. 2017;120(4)534–541. Doi: 10.1016/j.amjcard.2017.05.020.

34. Balta S, Celik T, Ozturk C. et al. The relation between monocyte to HDL ratio and no-reflow phenomenon in the patients with acute ST-segment elevation myocardial infarction // The American Journal of Emergency Medicine. 2016; 34(8):1542–1547. Doi: 10.1016/j.ajem.2016.05.031.

35. Wang J, Chen Y, Wang C. et al. The impact of preprimary percutaneous coronary intervention β blocker use on the no-reflow phenomenon in patients with acute myocardial infarction // Chin. J. Cardiol. 2014;42(10):822–826.

36. Celik T, Kaya MG, Akpek M. Does serum bilirubin level on admission predict timi flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI // Angiology. 2014;65(3):198–204. Doi: 10.1177/0003319712474948.

37. Zhao J, Yang Y, Zhang Y. et al. Chronic pretreatment of ACEI reduces no-reflow in patients with acute myocardial infarction treated with primary angioplasty // Clin. Cardiol. 2007;30(3):130–134. Doi: 10.1002/clc.20060.

38. Iwakura K, Ito H, Kawano S. et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction // Eur Heart J. 2006;27(5):534–539. Doi: 10.1093/eurheartj/ehi715.

39. Kim JS, Kim J, Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial // JACC Cardiovasc Interv. 2010; 3(3):332–339. Doi: 10.1016/j.jcin.2009.11.021.

40. Hu T, Wang HC, Wang RT. et al. Effect of chronic pretreatment of angiotensin-converting receptor blocker on no-reflow phenomenon in patients with acute myocardial infarction undergoing percutaneous coronary intervention // Cardiovascular Therapeutics. 2013;31(3):7–11. Doi: 10.1111/j.17555922.2012.00314.x.

41. Wang JW, Zhou ZQ, Chen YD. et al. A risk score for no reflow in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention // Clinical Cardiology. 2015;38(4):208–215. Doi:10.1002/clc.22376.

42. LiY, Hongliang C, Yali L. et al. Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Medicine (Baltimore). 2020;99(26):E20152. Doi: 10.1097/MD.0000000000020152.